Douglas Hunt, B.Sc (Hons).
Senior Vice President, Regulatory Affairs, Medical Writing and Project Management
Mr. Hunt joined Puma Biotechnology as Senior Vice President of Regulatory Affairs, Medical Writing and Project Management in January 2018.
Mr. Hunt was Vice President of Regulatory Affairs and Quality Assurance at Armagen Inc, from April 2015 to December 2017, where he supported the continuing development of multiple products designed to cross the Blood Brain Barrier. He served as Vice President Global Regulatory Affairs for Baxter Healthcare from 2008 to 2015. During his tenure at Baxter he led a team responsible for gaining global approvals in various bleeding disorders, influenza and the treatment of various immune deficiencies. Notably, he supported the successful U.S. advisory Committee that supported the approval of HyQuvia. From March 2000 to July 2008, Mr. Hunt held various roles at Amgen, including Therapeutic Area lead in Inflammation and Oncology. During his tenure at Amgen, he supported the development and approval of Neulasta, Aranesp, Enbrel and NPlate. Prior to joining Amgen, Mr. Hunt worked for Quintiles, providing regulatory support to multiple development programs.
Mr. Hunt received a B.Sc from the University of Portsmouth (UK). He is a Fellow of the Regulatory Affairs Professionals Society.
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024